George Theodorakopoulos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cellular, Acellular, and Matrix‐Like Placental Products for Diabetic Foot Ulcers: A 12‐Week Randomised‐Trial Meta‐Analysis

    by George Theodorakopoulos, David G. Armstrong

    Placental‐derived cellular, acellular, and matrix‐like products (CAMPs) are widely used as adjuncts to standard care for diabetic foot ulcers (DFUs), but trials differ in product class, comparator, and healing window. We estimated the effect of adjunctive placental‐derived CAMPs on complete wound closure at a single, clinically meaningful 12‐week endpoint. The review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261399700) and reported per Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020, with search reporting guided by PRISMA‐S. PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 21 June 2026 for randomised or quasi‐randomised trials comparing a placental, amniotic, chorionic, amnion‐chorion, placental membrane, or umbilical cord‐derived product plus standard care against standard care or a non‐placental control in adults with active DFUs. The primary outcome was complete wound closure at 12 weeks. Risk ratios (RRs) were pooled in a random‐effects model (inverse‐variance, restricted maximum likelihood [REML], Hartung‐Knapp). Risk of bias was assessed with the Cochrane Risk of Bias 2 tool (RoB 2) for the 12‐week outcome and certainty with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Prespecified sensitivity analyses included odds ratios, leave‐one‐out, product‐class subgroups, and exclusion of high‐risk‐of‐bias studies. Of 474 records, 14 randomised articles were retained; 9 standard‐care‐controlled comparisons (944 participants) provided extractable 12‐week complete‐closure data for the primary analysis. Complete closure occurred in 298 of 505 product‐treated participants (59.0%) versus 157 of 439 controls (35.8%). Adjunctive CAMPs increased the likelihood of closure (RR 1.70, 95% confidence interval [CI] 1.31–2.20). Heterogeneity was moderate (I 2 = 51.9%) and the prediction interval crossed the null (0.93–3.11). The effect was robust to leave‐one‐out analysis (RR 1.59–1.81), an odds‐ratio model (odds ratio [OR] 3.36, 95% CI 1.68–6.71), and exclusion of the single high‐risk‐of‐bias trial (RR 1.73, 95% CI 1.29–2.33). Certainty was moderate, downgraded once for inconsistency. Adjunctive placental‐derived CAMPs improve 12‐week complete closure of DFUs compared with standard care, with moderate certainty. The wide prediction interval indicates that the average benefit may not be reproduced by every product, population, or setting, underscoring the need for product‐specific, standard‐care‐anchored trials and for coverage policy grounded in endpoint‐specific randomised evidence. Trial Registration: Registration number: CRD420261399700.


  • Open Access

    Beyond the Surface: Clinical Insights into Diabetic Foot Ulcer Biofilm, Chronic Inhibitory Bacterial Load, and Sharp Debridement

    by George Theodorakopoulos, Thomas G. Mast, Hikmet Erhan Güven, Thomas E. Serena, David G. Armstrong

    Background: Diabetic foot ulcers (DFUs) are frequently complicated by high bacterial burden and biofilm, yet the practical implications for sharp debridement remain uncertain. This review examined where bacterial burden and biofilm are located in DFUs, how far debridement should extend, what may remain after debridement, and how often the procedure should be repeated. Methods: PubMed, Scopus, and CENTRAL were searched, with additional targeted hand-searching, and 33 publications were included in the narrative synthesis. Results: The evidence showed that substantial bacterial burden may be present even in wounds without obvious clinical signs and may extend into the wound edge and periwound tissue. Biofilm-like structures have been demonstrated directly in DFU tissue, but direct clinical evidence of complete biofilm removal remains limited. Adequate debridement was associated with better healing, although no validated depth, fixed margin, or bleeding endpoint was identified. Studies measuring bacterial burden before and after debridement consistently suggested reduction rather than complete clearance. Evidence on frequency was less straightforward: large observational studies associated more frequent debridement with faster healing, whereas randomized evidence found no clear advantage of weekly over every-second-week debridement in selected neuropathic DFUs. Fluorescence imaging may help identify residual or clinically unsuspected bacterial burden and can alter the extent or location of debridement. Conclusions: Overall, sharp debridement remains an important part of DFU care, but the available evidence supports a flexible, wound-guided approach rather than rigid procedural rules. More work is needed to define objective endpoints for debridement adequacy, biofilm removal, and repeat treatment.

  • Open Access

    Local Action, Systemic Reach: A Topical Desiccating Agent in Diabetic Foot-Related Necrotizing Fasciitis—A Retrospective Cohort Study

    by Hikmet Erhan Güven, Lara Kavasoğlu, George Theodorakopoulos

    Background: Necrotizing fasciitis complicating diabetic foot infection requires rapid source control and is associated with substantial morbidity. A topical desiccating agent (TDA) may assist debridement by dehydrating necrotic tissue and potentially disrupting biofilm, but comparative clinical evidence is limited. Methods: We conducted a retrospective, single-center cohort study of 87 patients who underwent emergency surgery for diabetic foot-related necrotizing fasciitis between July 2023 and February 2026. Nineteen patients received a single application of TDA at the index operation in addition to standard care, and 68 received standard care without TDA. Treatment allocation was non-random and occurred in routine clinical practice. The primary outcome was the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score at Day 7. The primary analysis used linear regression adjusted for baseline LRINEC score and baseline septic status, with heteroskedasticity-consistent type 3 (HC3) standard errors. LRINEC was treated as a laboratory-based surrogate rather than as a validated treatment-response measure. C-reactive protein (CRP), white blood cell count, and glucose at Day 0 and Day 7 were summarized descriptively. Secondary clinical outcomes were 30-day major amputation and all-cause mortality. Results: The mean LRINEC score decreased from 8.58 to 2.95 in the TDA group and from 7.51 to 5.51 in the control group. The mean change was −5.63 in the TDA group and −2.00 in the control group, an unadjusted between-group difference of −3.63 points (95% confidence interval [CI], −4.83 to −2.43; p < 0.001). Baseline sepsis was more frequent in the TDA group than in the control group (89.5% vs. 51.5%). After adjustment for baseline LRINEC score and septic status, TDA exposure was associated with a 3.01-point lower Day-7 LRINEC score (95% CI, −4.00 to −2.02; p < 0.001). At Day 7, 18 of 19 TDA-treated patients (94.7%) and 34 of 68 controls (50.0%) had an LRINEC score below 6; this threshold analysis was exploratory. CRP, white blood cell count, and glucose decreased descriptively in both groups, with numerically larger reductions in the TDA group. No major amputations or deaths occurred within 30 days in either group. No TDA-related adverse event was documented in the retrospective clinical records. Conclusions: Adjunctive TDA use was associated with a lower Day-7 LRINEC score and a greater reduction from baseline. Because treatment was not randomized, baseline severity differed between groups, LRINEC is not a validated longitudinal treatment-response measure, and assessment of clinical outcomes was limited, the findings should be interpreted as exploratory associations and confirmed in prospective multicenter studies.

  • Open Access

    Less Is More? Physical Inactivity and Increased Risk of Diabetes‐Related Foot Ulceration—A Systematic Review

    by Petra J. Jones, David G. Armstrong, Alex V. Rowlands, Harald Sourij, Afsaneh Noormandi, George Theodorakopoulos

    Aims: Those at risk of diabetes‐related foot ulceration (DFU) must balance sufficient physical activity to maintain glycaemic control and cardiovascular health whilst avoiding excessive trauma to their feet. Our systematic review aimed to assess whether physical inactivity and/or sedentary behaviour affect DFU outcomes. Materials and Methods: Embase, Medline, and Scopus were searched for peer‐reviewed studies using the criteria: (‘diabetes’ OR ‘diabetic’) AND (‘physical*’ OR ‘activ*’ OR ‘inactiv*’ OR ‘sedentary’) AND ‘foot’ AND ‘ulcer’, returning 4650 results excluding duplicates. 16 studies were included and assessed for risk of bias using the Newcastle‐Ottawa Scale (NOS). Results: Fifteen studies assessed physical inactivity and 1 assessed both inactivity and sedentary behaviour and DFU outcomes. Eleven of 16 (69%) studies reported significantly greater likelihood of DFU in inactive participants. Exploratory meta‐analysis suggested physical inactivity to be associated with doubled DFU risk (OR 2.09, 95% CI 1.32–3.32, p = 0.002). Evidence that sedentary behaviour was associated with tripled DFU risk was based on a single prospective cohort and had a high risk of bias (OR 2.95, 95% CI: 1.5–6.4, p = 0.008; n = 175, NOS: poor). Study methodologies were heterogenous (e.g., inconsistent definitions of inactive), with habitual physical activity measured through interviews, patient records, or questionnaires in 14 of 16 studies (NOS rating: poor to fair). Conclusions: Available evidence suggested that physical inactivity and sedentary behaviour were associated with an increased risk of DFU. Further research is needed to develop thresholds for physical inactivity and sedentary behaviour to reduce DFU risk.


  • Topical Oxygen Therapy for Diabetic Foot Ulcers: Updated Evidence From Randomised Trials

    by George Theodorakopoulos, David G. Armstrong

    To estimate the effect of topical oxygen therapy (TOT) on complete wound closure in diabetic foot ulcers (DFUs) at 12 weeks. We systematically reviewed randomised controlled trials in adults with DFUs comparing TOT to sham or standard care. Study selection and data extraction followed predefined criteria, with uncertainties discussed between the authors. Risk of bias was assessed with RoB 2. The primary outcome was complete closure at 12 weeks. Risk ratios (RRs) were pooled using a Mantel–Haenszel fixed‐effect model with χ 2 and I 2 to assess heterogeneity. Random‐effects sensitivity analyses were performed, including DerSimonian–Laird and Hartung–Knapp adjustment given the small number of studies. Three trials ( n = 171 TOT; n = 154 control) reported 12‐week closure and were pooled. TOT increased complete closure (RR 1.53, 95% CI 1.14–2.05). Heterogeneity was low ( I 2 ≈24%). The DerSimonian–Laird random‐effects model produced a similar point estimate (RR 1.50, 95% CI 1.07–2.10), while Hartung–Knapp adjustment yielded wider uncertainty. No zero cells were present; the prespecified continuity correction was not required. Across randomised trials with a 12‐week assessment, TOT used alongside standard care increases the likelihood of complete closure in DFUs, with low between‐study heterogeneity. These conclusions are based on three pooled randomised trials, and conservative Hartung–Knapp sensitivity analysis widened uncertainty, reflecting the limited size of the evidence base. However, with few trials, uncertainty remains; larger, well‐reported studies with standardised endpoints and blinded outcome verification are needed to refine precision and compare delivery approaches.


  • Open Access

    The First Year of Remission: A Systematic Review and Meta-Analysis of 12-Month Diabetic Foot Ulcer Recurrence

    by George Theodorakopoulos, David G. Armstrong

    Background: Preventing diabetic foot ulcer (DFU) recurrence after healing is a major challenge in the remission phase. In this context, remission is not synonymous with healed; it refers to a confirmed post-healing state in which the ulcer is closed, but the individual remains at high risk of recurrence and requires ongoing preventive care. Armstrong, Boulton, and Bus suggested that DFU recurrence is about 40% at 1 year, 60% at 3 years, and 65% at 5 years and argued that limb preservation should follow a long-term “survivorship” model similar to cancer care. However, these estimates combine heterogeneous follow-up intervals and definitions, and there is limited work focusing specifically on the first 12 months after confirmed remission. Methods: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Searches of PubMed/MEDLINE, Scopus, ScienceDirect, and the Cochrane Library were performed on 16 December 2025. Eligible studies enrolled adults with diabetes in confirmed remission after a healed DFU and reported an exact 12-month recurrence outcome (n/N or Kaplan–Meier estimate). Risk of bias was assessed using the Critical Appraisal Skills Program and Joanna Briggs Institute tools, and certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Twelve-month recurrence proportions were pooled using a random-effects model on the logit scale, and results were interpreted cautiously due to the limited number of eligible cohorts. Results: Across three cohorts with confirmed remission at baseline (total n = 469) and an exact 12-month outcome, the pooled 12-month recurrence proportion was 29.3% (random-effects; 95% CI 24.9–34.1), i.e., about one in three. Although this estimate is lower than the widely cited ~40% 1-year recurrence benchmark, it reflects a strictly defined remission population and a fixed 12-month timepoint, rather than mixed follow-up intervals or less precise definitions. Conclusions: Approximately one in three adults in remission after a healed DFU develop a recurrent ulcer within 12 months. Because this estimate is based on a small number of cohorts and on strictly confirmed remission, it should be interpreted cautiously and should not be generalized to all individuals with a healed DFU. These findings support prevention-focused surveillance and ongoing risk management during remission. Larger, preregistered multicenter cohorts with standardized remission and recurrence definitions are needed to refine short-term recurrence estimates and inform survivorship-style models of care.

  • Open Access

    Biofilm in Diabetic Foot Ulcers: A Systematic Narrative Review

    by George Theodorakopoulos, David G. Armstrong

    Biofilms are a key driver of chronicity and treatment failure in diabetic foot ulcers (DFUs), yet clinical evidence quantifying their impact and management remains fragmented. This systematic narrative review synthesised recent evidence (2015–2025) on the prevalence, diagnostics, and management of biofilm in DFUs. A Systematic Review of the Literature (SRL) was conducted following PRISMA 2020 guidelines across PubMed/MEDLINE, Scopus, Cochrane Library and ScienceDirect. Eligible studies included adults with DFUs reporting biofilm/bioburden metrics or interventions aimed at biofilm disruption. Risk of bias was assessed using RoB 2 for randomised trials and ROBINS‐I for non‐randomised studies. Data were narratively synthesised by evidence tier (Tier 1 = clinical; Tier 2 = preclinical/mechanistic). Of 600 records screened, 25 studies met inclusion criteria (Tier 1 n = 9; Tier 2 n = 5; reviews n = 11). Over half of bacterial isolates in DFUs were biofilm producers, with multidrug resistance exceeding 90% in several cohorts. Fungi were detected in 31% of ulcers by qPCR but only 9% by culture. Tier 1 clinical evidence supports standard care components—debridement, antiseptics, and negative‐pressure wound therapy—for improved healing, though direct antibiofilm outcomes remain limited. Emerging strategies (enzymatic agents, peptides, cold plasma, smart dressings) show promise in vitro but lack clinical translation. Evidence for direct antibiofilm efficacy in DFUs remains scarce. Current data justify maintaining guideline‐based care while prioritising trials that integrate validated biofilm endpoints, standardised microbiological methods, and antifungal components. Distinguishing established from experimental approaches is essential to advancing safe, evidence‐based biofilm management in DFUs.


  • Open Access

    Collagen– ORC Versus Standard Treatment in Diabetic Foot Ulcers: A Systematic Review and Meta‐Analysis of Randomised Trials

    by George Theodorakopoulos, David G. Armstrong

    Diabetic foot ulcers (DFUs) are a major cause of infection, hospitalisation, and amputation. Collagen‐based dressings—especially collagen combined with oxidised regenerated cellulose (ORC)—are proposed to improve healing by modulating matrix metalloproteinases (MMPs), stabilising the extracellular matrix (ECM), and tempering inflammation; some formulations also include antimicrobial or bioactive adjuncts. We conducted a systematic review of randomised controlled trials (RCTs) following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidance. Adults with DFUs were eligible. Interventions included collagen‐alone or collagen‐combination dressings (e.g., collagen–oxidised regenerated cellulose [collagen–ORC]/silver, collagen–chitosan) versus standard of care (SOC) or alternative dressings. To ensure comparable outcomes, the quantitative synthesis was pre‐specified and restricted to complete wound closure (yes/no, intention‐to‐treat [ITT]) from collagen‐combination RCTs with aligned constructs; other outcomes were synthesised narratively. Meta‐analyses were performed in Microsoft Excel using Mantel–Haenszel methods for risk ratios (RR) with a fixed‐effect primary model and DerSimonian–Laird random‐effects sensitivity analysis; heterogeneity was summarised with Cochran's Q, between‐study variance ( τ 2 ), and Higgins' I 2 statistic ( I 2 ), and a 95% prediction interval was reported for random‐effects. (Protocol not registered). Six studies (five randomized controlled trials and one single‐blinded non‐randomized comparative study; total n = 314) met inclusion. In a focused meta‐analysis of the two collagen‐combination RCTs, treatment was associated with a higher probability of complete wound closure versus control (RR 1.69, 95% confidence interval [CI] 1.05–2.72; I 2 = 0%). One assessor‐blinded RCT of collagen alone reported higher 12‐week closure versus a placebo dressing and was not pooled due to heterogeneity. Across studies, signals also favored collagen‐based care for earlier area reduction and, in one trial, fewer infection‐related withdrawals; mechanistic work showed reductions in MMP‐9/TIMP‐2. However, most trials were small and single‐centre, comparators and adjuncts varied, follow‐up was short (~8 days–24 weeks, clinical endpoints typically 4–20 weeks), outcome definitions were non‐standardised, and key confounders (off‐loading, infection management, vascular status, glycaemic control) were inconsistently addressed. Collagen‐based dressings—particularly collagen‐combination formulations—appear to improve complete closure when added to the standard of care (SOC) for diabetic foot ulcers (DFUs), but the evidence is limited by study size, heterogeneity, and risk of bias. Larger, prospectively registered, multicentre RCTs with standardised outcomes and longer follow‐up are needed to define clinical and cost‐effectiveness and to identify which patients benefit most. Collagen–ORC dressings show promise as an adjunctive treatment for DFUs by influencing the inflammatory microenvironment and supporting tissue repair. However, the certainty of the current evidence remains limited, highlighting the need for further high‐quality randomised studies.


  • Open Access

    Negative-Pressure Wound Therapy in Diabetic Foot Management: Synthesis of International Randomized Evidence over Two Decades

    by George Theodorakopoulos, David G. Armstrong

    Background: Diabetic foot ulcers (DFUs) carry high risks of infection, amputation, and mortality. We systematically reviewed randomized controlled trials (RCTs) of negative-pressure wound therapy (NPWT), including single-use systems, for clinically uninfected DFUs (with sensitivity analyses for mixed/infected cohorts). Methods: We searched PubMed and Scopus (1 January 2004–30 June 2024). Dual reviewers performed screening and extraction; risk of bias was assessed with Cochrane Risk of Bias 2 (RoB 2) and certainty of evidence with GRADE. When ≥2 trials reported comparable outcomes, we used random-effects meta-analysis. The DiaFu cohort reported in two publications was counted once across analyses. Results: Eleven RCT publications (n = 1699; 10 unique cohorts) met criteria; eight trials (n = 1456) informed the primary endpoint. Trials largely excluded severe ischemia; findings therefore apply mainly to neuropathic or mixed-etiology DFUs with adequate perfusion. NPWT increased complete healing at 12–16 weeks (risk ratio [RR] 1.46, 95% CI 1.21–1.76; I2 = 48%) and shortened time to healing (mean difference –18 days, 95% CI −28 to −8). Effects were similar for conventional and single-use NPWT. Outcomes did not vary systematically within commonly used pressure ranges (approximately −80 to −125 mmHg). Only two RCTs reported direct cost data (exploratory). Moderate heterogeneity (Higgins’ I2 48–68%) reflected variation in ulcer severity, device type/settings, dressing-change frequency, and off-loading protocols. Conclusions: NPWT probably improves short-term healing of clinically uninfected DFUs compared with standard care and may reduce minor amputations, without increasing adverse events. Certainty is moderate for healing and low for most secondary outcomes. Benefits appear consistent across device classes and may support earlier discharge and community-based care. Evidence gaps include ischemia-dominated ulcers, long-term outcomes (recurrence and limb preservation), adherence mechanisms, and contemporary cost-effectiveness.